What Treatment-Resistant Depression Actually Means for You

Treatment-resistant depression is a clinical condition defined by inadequate response to standard antidepressant treatment, but up to half of cases involve treatable, modifiable factors, and evidence-based psychotherapies such as Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and Mindfulness-Based Cognitive Therapy provide clinically supported pathways to relief when combined with a structured, personalized treatment approach.

If your antidepressants have not worked, you may not actually have treatment-resistant depression, at least not in the way your provider has framed it. Up to half of apparent TRD cases involve fixable factors being overlooked. This guide breaks down what true resistance means, and what meaningful options still remain.

Before escalating treatment: factors that create the appearance of resistance

Not every case of apparent treatment-resistant depression (TRD) reflects a true biological failure to respond. A significant share of cases, some estimates suggest up to 50%, involve what clinicians call pseudoresistance: a situation where modifiable factors make depression look like it is not responding when the real problem lies elsewhere. Identifying these factors before pursuing more aggressive treatments is one of the most important steps you and your provider can take.

A 12-point screening checklist to review before your next appointment

Go through each item below and note anything that applies to your situation. Bringing this list to your provider gives them the clearest possible picture of what may be driving your symptoms.

1. Adherence: Have you been taking your medication consistently, at the same time each day, without skipping doses?
2. Duration: Did you take the medication for at least 6 to 8 weeks at a therapeutic dose before concluding it did not work?
3. Dosing: Was your dose ever adjusted upward, or did you stay at the starting dose throughout the trial?
4. Thyroid function: Have you been screened for hypothyroidism or other thyroid disorders recently? Thyroid dysfunction can directly blunt antidepressant response.
5. Bipolar spectrum: Has a clinician ever explored whether your depression may be part of a bipolar spectrum disorder? Antidepressants alone can be ineffective or destabilizing in that context.
6. ADHD: Undiagnosed ADHD can mimic and worsen depressive symptoms, making standard treatments appear to fail.
7. Sleep disorders: Obstructive sleep apnea causes chronic fatigue and low mood that no antidepressant can fully overcome if the apnea goes untreated.
8. Chronic pain: Ongoing physical pain and depression share overlapping neurological pathways, and each condition can sustain the other.
9. Substance use: Active alcohol or drug use, even at levels that feel manageable, can significantly undermine antidepressant effectiveness.
10. Comorbid anxiety: Anxiety symptoms frequently co-occur with depression, and undiagnosed comorbidities can meaningfully undermine treatment response when they go unaddressed.
11. Pharmacokinetics: Your body’s metabolism of medication matters. Genetic variations in enzymes like CYP2D6 and CYP2C19 can cause some people to clear antidepressants too quickly, making standard doses ineffective, while others metabolize them too slowly and experience side effects that lead to early discontinuation.
12. Psychosocial stressors: Ongoing trauma exposure, untreated relationship conflict, financial crisis, or deep social isolation can overwhelm what any medication is capable of doing on its own.

Working through this checklist is not about second-guessing your past care. It is about making sure that every addressable factor has been considered before you and your provider move toward more intensive options.

How severe is your treatment resistance? The clinical staging models explained

Not all treatment-resistant depression looks the same. Researchers developed clinical staging models to map out exactly where a person is in the treatment process, and two of the most widely used are the Thase-Rush Staging Model and the Massachusetts General Hospital (MGH) Staging Method. Understanding these frameworks can help you have a more grounded, specific conversation with your provider about what comes next.

The Thase-Rush staging model: stages I through V

The Thase-Rush model organizes TRD into five stages based on which treatment trials have not produced adequate relief:

• Stage I: One adequate trial of a first-line antidepressant, typically an SSRI (selective serotonin reuptake inhibitor), has not worked.
• Stage II: A second adequate trial from a different medication class has also not worked.
• Stage III: A trial of a tricyclic antidepressant (an older class of medication) has not produced a response.
• Stage IV: A trial of an MAOI (monoamine oxidase inhibitor, another older antidepressant class) has not worked.
• Stage V: Bilateral ECT (electroconvulsive therapy, a procedure that uses electrical stimulation to trigger brief brain activity changes) has not produced adequate relief.

Each stage signals that a higher tier of treatment is clinically appropriate to consider.

The MGH staging method

The MGH Staging Method takes a more granular approach. Rather than simple pass-or-fail categories, it uses a continuous scoring system that accounts for the number of failed trials, whether each trial was properly optimized (correct dose, correct duration), and whether augmentation strategies were tried. Augmentation means adding a second medication or treatment to boost the effect of the first. This scoring gives clinicians a more precise picture of where a person stands.

What staging means for you

Staging is a clinical tool, not a measure of how much you are suffering. A person at Stage I is not less ill than someone at Stage V. They are simply earlier in the treatment algorithm. Knowing your stage helps clarify which options are appropriate to explore next and why your provider may be recommending something beyond a standard first-line approach. This kind of structured thinking applies across the full spectrum of mood disorders, helping both patients and providers move forward with a clearer plan.

Medication strategies beyond the first antidepressants

When one or two antidepressants have not worked, your prescriber is not out of options. There are three well-established pharmacological strategies for TRD: switching to a different medication class, combining two antidepressants with complementary mechanisms, or augmenting your current medication with a non-antidepressant agent. Each approach has a distinct rationale, and the right path depends on your individual clinical profile, side effect history, and how you responded to previous treatments.

Switching antidepressant classes

Switching means moving from one category of antidepressant to a chemically different one. For example, if an SSRI did not work, a prescriber might move to an SNRI (serotonin-norepinephrine reuptake inhibitor), bupropion, mirtazapine, or a tricyclic antidepressant. Switching within the same class targets the same brain pathways and offers limited additional benefit for most people. Switching classes engages different neurotransmitter systems, which may be a better match for your biology. This process typically involves a cross-taper, where the old medication is gradually reduced while the new one is slowly introduced, to minimize withdrawal effects and maintain stability throughout the transition.

Combining antidepressants with complementary mechanisms

Combination therapy means using two antidepressants simultaneously, specifically ones that work through different pathways so they complement rather than duplicate each other. One widely studied example is pairing an SSRI with bupropion, which adds dopamine and norepinephrine activity to the serotonin focus of the SSRI. Another is the SSRI plus mirtazapine combination, sometimes called “California Rocket Fuel” in clinical shorthand, which layers serotonin reuptake inhibition with mirtazapine’s distinct receptor-blocking effects. The evidence favors combinations with clearly different mechanisms over those that simply stack similar drugs. As with any multi-medication approach, the risk of interactions and side effects requires careful monitoring by a prescriber.

Augmentation with non-antidepressant medications

Augmentation means adding a medication that is not classified as an antidepressant to boost the effect of your existing one. This strategy has strong research support. Atypical antipsychotics are among the most studied augmentation agents: aripiprazole, quetiapine, and brexpiprazole have all shown response rate improvements of roughly 30 to 50 percent in meta-analyses of TRD populations. Lithium, long used in bipolar disorder, is another established option with decades of evidence behind it. Thyroid hormone (specifically T3) and buspirone are also used in certain clinical profiles. The right augmentation agent depends on factors like your side effect tolerance, other health conditions, and what your prescriber determines fits your overall picture.

These three strategies are categories, not prescriptions. Specific medication decisions require a licensed provider who can weigh your full history. Many people also find that pairing pharmacological changes with therapy, such as cognitive behavioral therapy, strengthens outcomes in ways that medication alone may not achieve.

Ketamine and esketamine: what these newer options look like in practice

Ketamine-based treatments have drawn significant attention in recent years, and for good reason. They work differently from traditional antidepressants by targeting NMDA receptors and rapidly increasing glutamate signaling in the brain. This distinct mechanism is exactly why ketamine can work when other medications have not.

IV ketamine

Intravenous (IV) ketamine is typically delivered through an induction protocol of six infusions spread over two to three weeks. Many people notice mood improvements within hours to days of their first infusion, which is a striking contrast to the weeks-long wait associated with standard antidepressants. The honest limitation is durability. For many people, the response fades within two to three weeks without ongoing maintenance infusions, meaning ketamine is rarely a one-and-done solution. Because IV ketamine is not FDA-approved specifically for depression, it falls outside standard insurance coverage, and each infusion typically costs between $400 and $800 out of pocket.

Esketamine (Spravato)

Esketamine, sold under the brand name Spravato, is the FDA-approved option specifically for treatment-resistant depression. It is administered as a nasal spray, but it cannot be taken at home. It must be used in a certified healthcare setting under medical supervision, as part of a REMS program (a Risk Evaluation and Mitigation Strategy, meaning a safety protocol required by the FDA). The induction phase involves twice-weekly sessions for four weeks, followed by weekly and then biweekly maintenance dosing. Clinical trials have shown acute response rates in the range of 50 to 70 percent, though relapse risk upon discontinuation remains real. Spravato does have insurance pathways, but expect prior authorization requirements and documented proof that multiple prior treatments have failed.

Neuromodulation therapies: ECT, TMS, and VNS

When medications and therapy have not moved the needle, neuromodulation offers a different approach entirely. Rather than targeting brain chemistry through drugs, these treatments use electrical or magnetic energy to directly influence neural activity. All three options discussed here are non-pharmacological and can be used alongside existing medication and therapy.

Electroconvulsive therapy: what modern ECT actually involves

ECT carries decades of stigma from outdated portrayals, but the reality of modern treatment looks nothing like those old images. Today’s ECT uses ultra-brief electrical pulses delivered under general anesthesia, meaning you are asleep throughout the procedure and feel nothing. A typical course runs 6 to 12 sessions over 3 to 4 weeks, often followed by periodic maintenance sessions to sustain results.

For severe TRD, ECT remains the most effective acute intervention available, with response rates between 50 and 70 percent. The shift from older bilateral sine-wave protocols to ultra-brief pulse techniques has significantly reduced the cognitive side effects, particularly memory difficulties, that made earlier versions of the treatment so concerning.

Transcranial magnetic stimulation: standard, deep, and accelerated protocols

Transcranial magnetic stimulation, or TMS, uses magnetic pulses to stimulate specific regions of the brain involved in mood regulation. It is FDA-cleared for TRD, requires no anesthesia, and is performed while you sit in a chair fully awake. Standard repetitive TMS (rTMS) protocols typically involve 20 to 30 daily sessions spread across 4 to 6 weeks.

Two variations expand on that foundation. Deep TMS (dTMS) uses specialized H-coils that reach deeper brain structures than standard coils can access. Accelerated protocols, most notably the Stanford SAINT approach, compress the entire treatment course into roughly five days by scheduling multiple sessions per day. This is particularly relevant for people who need faster results or have difficulty committing to weeks of daily appointments.

Vagus nerve stimulation: the long-horizon option

Vagus nerve stimulation (VNS) differs from the other two in a critical way: it requires a surgical procedure to implant a small device near the collarbone that delivers regular electrical pulses to the vagus nerve. The FDA has approved VNS for TRD, but it comes with an expectation that is essential to understand before pursuing it.

Meaningful clinical response typically takes 6 to 12 months to emerge. This is not a treatment for people in acute crisis. It is a long-horizon intervention for those who have already tried multiple other modalities without adequate relief. Because of the surgical requirement and the extended timeline, VNS is generally considered after other neuromodulation options have been explored.

Psychological therapies that complement TRD treatment

Psychotherapy is not a consolation prize when medications fall short. At the treatment-resistant stage, therapy addresses mechanisms that no pill can reach: learned helplessness patterns built over years, interpersonal dysfunction, and depression that is actively maintained by trauma or deeply ingrained thinking styles. Research on psychotherapy as augmentation in TRD supports its role as a meaningful complement to pharmacological and neuromodulation interventions, not a replacement for them.

Matching the therapy to the profile

Cognitive Behavioral Analysis System of Psychotherapy (CBASP) was specifically developed for chronic depression. It focuses on interpersonal patterns and situational analysis, helping you examine how your responses to others maintain depressive cycles. It tends to work best for people with early-onset chronic depression and a pattern of avoiding interpersonal connection.

Mindfulness-Based Cognitive Therapy (MBCT) carries the strongest evidence for relapse prevention in recurrent depression. It blends mindfulness practices with cognitive restructuring and is particularly effective for people who experience high levels of rumination, meaning repetitive, looping negative thinking.

Schema Therapy targets early maladaptive schemas, which are deep-seated beliefs about yourself and the world that formed early in life and continue driving depressive cycles despite medication. It is especially relevant when personality-related factors contribute to chronicity.

Behavioral Activation takes a more direct route: it systematically reverses the withdrawal and avoidance patterns that depression creates. When cognitive approaches feel out of reach because depression is severe, behavioral activation offers a structured, accessible entry point.

These modalities work on different levels and can often be combined. The goal is not to find one answer but to build a treatment plan that addresses what your current interventions are missing. If you want to explore therapy as part of your treatment plan, you can connect with a licensed therapist through ReachLink at no cost for your initial assessment, with no commitment required.

The emerging frontier: psilocybin, deep brain stimulation, and what may be coming

Research into treatment-resistant depression is moving quickly, and several investigational therapies are generating real interest in the psychiatric community. None of these are currently available as standard treatments, but understanding what is in the pipeline can help you have more informed conversations with your care team.

Psilocybin-assisted therapy

Psilocybin, the active compound in certain mushrooms, works by activating 5-HT2A receptors in the brain, which are serotonin receptors linked to mood regulation and perception. This activation appears to encourage neural plasticity, meaning the brain may become more capable of forming new patterns of thought and feeling. COMPASS Pathways is currently running Phase III clinical trials, and the FDA has granted psilocybin a Breakthrough Therapy designation, a status that accelerates the review process for promising treatments. Access today is limited to enrolled clinical trials.

Deep brain stimulation and pharmacogenomics

Deep brain stimulation (DBS) involves surgically implanting electrodes that deliver electrical pulses to a specific brain region called the subcallosal cingulate cortex (Brodmann area 25), which plays a role in regulating mood. Because it requires neurosurgery, DBS is being studied only for the most severe, refractory cases and remains investigational. Separately, pharmacogenomics-guided prescribing uses genetic testing to predict how a person metabolizes medications and responds to specific receptors, potentially reducing the trial-and-error process. The evidence base is growing, but this approach is not yet standard of care for TRD.

These developments are genuinely promising. At the same time, waiting for investigational options instead of pursuing established treatments that exist right now is rarely in your best interest.

Putting it together: how these options compare

No single treatment wins across every dimension. Each modality covered here involves real trade-offs between response rates, time to effect, session burden, side effects, and access. Understanding those trade-offs is what makes the difference between a passive patient and an informed one.

• Medication adjustments and augmentation: Widely accessible, low session burden, but response rates for each new trial drop with each prior failure. Pharmacogenomic testing can meaningfully improve targeting.
• Esketamine (Spravato): Faster onset than most oral medications, with response seen in days for some people. Requires in-office administration twice weekly at first, which is a real access and scheduling consideration.
• TMS (transcranial magnetic stimulation): Non-invasive, no systemic side effects, but requires 20 to 36 sessions over several weeks. Response rates in TRD range from roughly 50 to 60 percent.
• ECT (electroconvulsive therapy): Highest response rates of any intervention in severe TRD, often 60 to 80 percent, but carries cognitive side effects and significant stigma that can delay access.
• Psychotherapy (especially CBASP and MBCT): Low risk, builds durable skills, but works best alongside other treatments rather than as a standalone option in severe TRD.

This comparison is a starting point for conversations with your provider, not a self-selection tool. Your staging level, comorbidities, and prior treatment history all shape which options are clinically appropriate for you. Treatment-resistant depression almost always calls for a multimodal approach, combining pharmacological, neuromodulation, and psychological interventions. The path is also iterative: new information, like pharmacogenomic results, can make earlier options worth revisiting.

While you work with your provider on a treatment plan, tools like ReachLink’s mood tracker and journal can help you monitor your symptoms and identify patterns between appointments, free to use, at your own pace.

You Have Already Done So Much of the Hard Work

If you have read this far, you are likely someone who has tried, waited, hoped, and tried again. That persistence in the face of something as exhausting as treatment-resistant depression deserves to be named. The options laid out here are not a promise that the next thing will work, but they are evidence that there are still meaningful paths forward, and that what you are experiencing has a name, a framework, and people who understand it.

You do not have to sort through these options alone or figure out which ones apply to your situation without support. If having a therapist in your corner, someone to help you track what is changing and advocate alongside you, feels like a missing piece, you can explore therapy through ReachLink at no cost for your first assessment, with no commitment required, and at whatever pace feels right for you.